Cargando…
Acute onset of fingolimod-associated macular edema
PURPOSE: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...
Autores principales: | Soliman, Mohamed Kamel, Sarwar, Salman, Sadiq, Mohammad A., Jack, Loren, Jouvenat, Neil, Zabad, Rana K., Kedar, Sachin, Nguyen, Quan Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757484/ https://www.ncbi.nlm.nih.gov/pubmed/29503930 http://dx.doi.org/10.1016/j.ajoc.2016.09.005 |
Ejemplares similares
-
Diagnosis and Management of Fingolimod-Associated Macular Edema
por: Wang, Chunjiang, et al.
Publicado: (2022) -
Fingolimod-associated severe bilateral cystoid macular edema
por: Fukuoka, Hideki, et al.
Publicado: (2022) -
Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023) -
Continuing fingolimod after development of macular edema: A case report
por: Li, Vivien, et al.
Publicado: (2014) -
Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?
por: Pul, Refik, et al.
Publicado: (2016)